Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia
Image: FDA grants breakthrough therapy designation to SEP-363856 for schizophrenia. Photo: courtesy of The U.S. Food and Drug Administration/Wikipedia.org.
Image: FDA grants breakthrough therapy designation to SEP-363856 for schizophrenia. Photo: courtesy of The U.S. Food and Drug Administration/Wikipedia.org.